Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C

2011106 citationsJournal Articlehybrid Open Access

Authors

Jordi Bruix · Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Thierry Poynard · Sorbonne Université

Massimo Colombo · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Eugene R. Schiff · University of Miami

Kelly W. Burak · University of Calgary

E. Jenny Heathcote · University of Toronto

Thomas Berg

Abstract

Maintenance therapy with peginterferon alfa-2b is not warranted in all patients and does not prevent HCC. However, there is a potential clinical benefit of long-term suppressive therapy in patients with preexisting portal hypertension.

Topics & Keywords

Hepatitis C virus research Liver Disease and Transplantation Liver Disease Diagnosis and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gastroenterology

Volume 140, Issue 7, pp. 1990-1999

DOI: 10.1053/j.gastro.2011.03.010

Field-Weighted Citation Impact: 8.03